Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;56(4):721-728.
doi: 10.1002/ppul.25135. Epub 2020 Nov 2.

The respiratory impact of novel therapies for spinal muscular atrophy

Grace R Paul  1 , Courtney Gushue  2 , Kavitha Kotha  1 , Richard Shell  1
Affiliations
Review

The respiratory impact of novel therapies for spinal muscular atrophy

Grace R Paul et al. Pediatr Pulmonol. 2021 Apr.

Abstract

The phenotype of spinal muscular atrophy (SMA) has been changing with the recent availability of three FDA-approved treatments: intrathecal nusinersen, intravenous onasemnogene abeparvovec-xioi, and enteral risdiplam. The degree of improvement in muscle strength and respiratory health varies with SMA genotype, severity of baseline neuromuscular and pulmonary impairment, medication used, and timing of the first dose. A spectrum of pulmonary outcomes has been reported with these novel medications when used early and in conjunction with proactive multidisciplinary management of comorbidities. In this review, we summarize the reported impact of these novel therapies on pulmonary well-being and the improving trajectory of pulmonary morbidity, compared to the natural history of SMA. The importance of ongoing clinical monitoring albeit the improved phenotype is reiterated. We also discuss the limitations of the current SMA-therapy trials and offer suggestions for future clinical-outcome studies and long-term monitoring.

Keywords: SMA; respiratory outcomes; treatment.

PubMed Disclaimer

References

REFERENCES

    1. West JB. Respiratory Physiology-The Essentials. Lippincott Williams & Wilkins; 2020.
    1. Darras BT. Spinal muscular atrophies. Pediatr Clin North Am. 2015;62(3):743-66.
    1. Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810-817.
    1. Fauroux B, Khirani S. Neuromuscular disease and respiratory physiology in children: putting lung function into perspective. Respirology. 2014;19(6):782-91.
    1. Fitzgerald DA, Doumit M, Abel F. Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1. Paediatr Respir Rev. 2018;28:11-17.